Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events
Brongiel S, Rychalsky K, Luon D, Johnson A, Price C, Abdelghany O. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Annals Of Pharmacotherapy 2022, 57: 148-155. PMID: 35656843, DOI: 10.1177/10600280221094330.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsInstitutional review boardImmunosuppressive therapyAdverse eventsSymptom resolutionImmune-related adverse eventsSecond-line immunosuppressive therapyRetrospective medical record reviewSecond-line medicationsCommon Terminology CriteriaSecond-line therapySecond-line treatmentMedical record reviewDose of infliximabHigh response rateUniversity Institutional Review BoardGastrointestinal ImmuneIrAE treatmentSteroid failureTerminology CriteriaCheckpoint inhibitorsMost patientsRecord reviewInclusion criteriaPatients